The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry
The aim of this investigation was to evaluate the impact of recombinant human growth hormone (rhGH) therapy on height velocity (HV), estimated glomerular filtration rate (eGFR) and body mass index (BMI) in a large cohort of children with chronic kidney disease (CKD). We reviewed longitudinal data fr...
Gespeichert in:
| Veröffentlicht in: | Pediatric nephrology (Berlin, West) West), 2009-09, Vol.24 (9), p.1711-1717 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1717 |
|---|---|
| container_issue | 9 |
| container_start_page | 1711 |
| container_title | Pediatric nephrology (Berlin, West) |
| container_volume | 24 |
| creator | Seikaly, Mouin G. Waber, Pamela Warady, Bradley A. Stablein, Donald |
| description | The aim of this investigation was to evaluate the impact of recombinant human growth hormone (rhGH) therapy on height velocity (HV), estimated glomerular filtration rate (eGFR) and body mass index (BMI) in a large cohort of children with chronic kidney disease (CKD). We reviewed longitudinal data from patients enrolled in the chronic renal insufficiency registry of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Of the 7189 patients enrolled in the registry, 827 (11.5%) received rhGH. A total of 787 children with CKD previously rhGH naïve who received rhGH for 1–4 years (median 1.5 years) were paired with 787 control patients, and over 100 of the case–controls were followed for 4 years. The control group was matched for age, gender, height and length of time in the NAPRTCS registry. Height velocity was also compared to the general U.S. population. The eGFR of the treated group (37.5 ml/min per 1.73 m
2
) was significantly less than that of the control group (42.3 ml/min per 1.73 m
2
;
p
|
| doi_str_mv | 10.1007/s00467-009-1183-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_20702933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A382151602</galeid><sourcerecordid>A382151602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-151e0dac6dff3d6ff245fb182df714358a1dcffde793fb4ffad4d8c63c187fbd3</originalsourceid><addsrcrecordid>eNp1kl1vFCEUhonR2LX6A7wxxIveTYVhPhjvtqu2jfUjuia9IywcZmhmYQVGs_9e6mxSNRUuSA7P--YceBF6TskpJaR9FQmpmrYgpCso5awgD9CCVqwsaMevH6IF6RgtSEWvj9CTGG8IIbzmzWN0RDvG24Z3C6TXA2AwBlTC3uAwnF9g7_AAth8S_gGjVzbtsXQan324xNZhNdhRB3D4p00DXr1_8xpLHGDnw2-HlP0-Lj9_Wa--5mpvYwr7p-iRkWOEZ4fzGH1793a9uiiuPp1frpZXhaoJTwWtKRAtVaONYboxpqxqs6G81KbNY9VcUq2M0dB2zGwqY6SuNFcNU5S3ZqPZMTqZfXfBf58gJrG1UcE4Sgd-iqIkLSk7xjL48h_wxk_B5d5EmVfL27LJUDFDvRxBWGd8ClL14CDI0TswNpeXjJe574aUmT-9h89bw9aqewUnfwgGkGMaoh-nZL2Lf4N0BlXwMQYwYhfsVoa9oETcJkHMSRA5CeI2CYJkzYvDiNNmC_pOcfj6DJQzEPOV6yHcvcH_XX8BW_u7jg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222278726</pqid></control><display><type>article</type><title>The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Seikaly, Mouin G. ; Waber, Pamela ; Warady, Bradley A. ; Stablein, Donald</creator><creatorcontrib>Seikaly, Mouin G. ; Waber, Pamela ; Warady, Bradley A. ; Stablein, Donald</creatorcontrib><description>The aim of this investigation was to evaluate the impact of recombinant human growth hormone (rhGH) therapy on height velocity (HV), estimated glomerular filtration rate (eGFR) and body mass index (BMI) in a large cohort of children with chronic kidney disease (CKD). We reviewed longitudinal data from patients enrolled in the chronic renal insufficiency registry of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Of the 7189 patients enrolled in the registry, 827 (11.5%) received rhGH. A total of 787 children with CKD previously rhGH naïve who received rhGH for 1–4 years (median 1.5 years) were paired with 787 control patients, and over 100 of the case–controls were followed for 4 years. The control group was matched for age, gender, height and length of time in the NAPRTCS registry. Height velocity was also compared to the general U.S. population. The eGFR of the treated group (37.5 ml/min per 1.73 m
2
) was significantly less than that of the control group (42.3 ml/min per 1.73 m
2
;
p
< 0.001). The rhGH-treated group had a significantly greater HV standard deviation score (SDS) than the control group (
p
< 0.01) at each 6-months post-rhGH treatment initiation point for 2.5 years (
p
< 0.007). Among 220 pairs at 2 years, the height SDS of the rhGH group was 0.56 SDS higher than that of the control group (
p
< 0.05). Treatment with rhGH had no significant impact on the BMI or eGFR. As demonstrated in smaller cohorts, rhGH usage is associated with improved HV in children with CKD. In contrast, rhGH does not appear to have any impact on BMI or kidney function in this population of patients.</description><identifier>ISSN: 0931-041X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/s00467-009-1183-0</identifier><identifier>PMID: 19387689</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Age ; Body Height - drug effects ; Body Height - physiology ; Body Mass Index ; Care and treatment ; Child ; Chronic kidney failure ; Cohort Studies ; Collaboration ; Complications and side effects ; Creatinine ; Female ; Gender ; Glomerular Filtration Rate - drug effects ; Growth Disorders - drug therapy ; Growth Disorders - etiology ; Growth Disorders - physiopathology ; Growth hormones ; Health aspects ; Human Growth Hormone - therapeutic use ; Humans ; Kidney diseases ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - physiopathology ; Kidney transplants ; Male ; Medicine & Public Health ; Nephrology ; North America ; Original Article ; Pediatrics ; Recombinant Proteins - therapeutic use ; Registries ; Somatotropin ; Treatment Outcome ; Urology ; Velocity</subject><ispartof>Pediatric nephrology (Berlin, West), 2009-09, Vol.24 (9), p.1711-1717</ispartof><rights>IPNA 2009</rights><rights>COPYRIGHT 2009 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-151e0dac6dff3d6ff245fb182df714358a1dcffde793fb4ffad4d8c63c187fbd3</citedby><cites>FETCH-LOGICAL-c508t-151e0dac6dff3d6ff245fb182df714358a1dcffde793fb4ffad4d8c63c187fbd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00467-009-1183-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00467-009-1183-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19387689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seikaly, Mouin G.</creatorcontrib><creatorcontrib>Waber, Pamela</creatorcontrib><creatorcontrib>Warady, Bradley A.</creatorcontrib><creatorcontrib>Stablein, Donald</creatorcontrib><title>The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><addtitle>Pediatr Nephrol</addtitle><description>The aim of this investigation was to evaluate the impact of recombinant human growth hormone (rhGH) therapy on height velocity (HV), estimated glomerular filtration rate (eGFR) and body mass index (BMI) in a large cohort of children with chronic kidney disease (CKD). We reviewed longitudinal data from patients enrolled in the chronic renal insufficiency registry of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Of the 7189 patients enrolled in the registry, 827 (11.5%) received rhGH. A total of 787 children with CKD previously rhGH naïve who received rhGH for 1–4 years (median 1.5 years) were paired with 787 control patients, and over 100 of the case–controls were followed for 4 years. The control group was matched for age, gender, height and length of time in the NAPRTCS registry. Height velocity was also compared to the general U.S. population. The eGFR of the treated group (37.5 ml/min per 1.73 m
2
) was significantly less than that of the control group (42.3 ml/min per 1.73 m
2
;
p
< 0.001). The rhGH-treated group had a significantly greater HV standard deviation score (SDS) than the control group (
p
< 0.01) at each 6-months post-rhGH treatment initiation point for 2.5 years (
p
< 0.007). Among 220 pairs at 2 years, the height SDS of the rhGH group was 0.56 SDS higher than that of the control group (
p
< 0.05). Treatment with rhGH had no significant impact on the BMI or eGFR. As demonstrated in smaller cohorts, rhGH usage is associated with improved HV in children with CKD. In contrast, rhGH does not appear to have any impact on BMI or kidney function in this population of patients.</description><subject>Age</subject><subject>Body Height - drug effects</subject><subject>Body Height - physiology</subject><subject>Body Mass Index</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Chronic kidney failure</subject><subject>Cohort Studies</subject><subject>Collaboration</subject><subject>Complications and side effects</subject><subject>Creatinine</subject><subject>Female</subject><subject>Gender</subject><subject>Glomerular Filtration Rate - drug effects</subject><subject>Growth Disorders - drug therapy</subject><subject>Growth Disorders - etiology</subject><subject>Growth Disorders - physiopathology</subject><subject>Growth hormones</subject><subject>Health aspects</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - physiopathology</subject><subject>Kidney transplants</subject><subject>Male</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>North America</subject><subject>Original Article</subject><subject>Pediatrics</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Registries</subject><subject>Somatotropin</subject><subject>Treatment Outcome</subject><subject>Urology</subject><subject>Velocity</subject><issn>0931-041X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kl1vFCEUhonR2LX6A7wxxIveTYVhPhjvtqu2jfUjuia9IywcZmhmYQVGs_9e6mxSNRUuSA7P--YceBF6TskpJaR9FQmpmrYgpCso5awgD9CCVqwsaMevH6IF6RgtSEWvj9CTGG8IIbzmzWN0RDvG24Z3C6TXA2AwBlTC3uAwnF9g7_AAth8S_gGjVzbtsXQan324xNZhNdhRB3D4p00DXr1_8xpLHGDnw2-HlP0-Lj9_Wa--5mpvYwr7p-iRkWOEZ4fzGH1793a9uiiuPp1frpZXhaoJTwWtKRAtVaONYboxpqxqs6G81KbNY9VcUq2M0dB2zGwqY6SuNFcNU5S3ZqPZMTqZfXfBf58gJrG1UcE4Sgd-iqIkLSk7xjL48h_wxk_B5d5EmVfL27LJUDFDvRxBWGd8ClL14CDI0TswNpeXjJe574aUmT-9h89bw9aqewUnfwgGkGMaoh-nZL2Lf4N0BlXwMQYwYhfsVoa9oETcJkHMSRA5CeI2CYJkzYvDiNNmC_pOcfj6DJQzEPOV6yHcvcH_XX8BW_u7jg</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Seikaly, Mouin G.</creator><creator>Waber, Pamela</creator><creator>Warady, Bradley A.</creator><creator>Stablein, Donald</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TS</scope></search><sort><creationdate>20090901</creationdate><title>The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry</title><author>Seikaly, Mouin G. ; Waber, Pamela ; Warady, Bradley A. ; Stablein, Donald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-151e0dac6dff3d6ff245fb182df714358a1dcffde793fb4ffad4d8c63c187fbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Age</topic><topic>Body Height - drug effects</topic><topic>Body Height - physiology</topic><topic>Body Mass Index</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Chronic kidney failure</topic><topic>Cohort Studies</topic><topic>Collaboration</topic><topic>Complications and side effects</topic><topic>Creatinine</topic><topic>Female</topic><topic>Gender</topic><topic>Glomerular Filtration Rate - drug effects</topic><topic>Growth Disorders - drug therapy</topic><topic>Growth Disorders - etiology</topic><topic>Growth Disorders - physiopathology</topic><topic>Growth hormones</topic><topic>Health aspects</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - physiopathology</topic><topic>Kidney transplants</topic><topic>Male</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>North America</topic><topic>Original Article</topic><topic>Pediatrics</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Registries</topic><topic>Somatotropin</topic><topic>Treatment Outcome</topic><topic>Urology</topic><topic>Velocity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seikaly, Mouin G.</creatorcontrib><creatorcontrib>Waber, Pamela</creatorcontrib><creatorcontrib>Warady, Bradley A.</creatorcontrib><creatorcontrib>Stablein, Donald</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Physical Education Index</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seikaly, Mouin G.</au><au>Waber, Pamela</au><au>Warady, Bradley A.</au><au>Stablein, Donald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><stitle>Pediatr Nephrol</stitle><addtitle>Pediatr Nephrol</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>24</volume><issue>9</issue><spage>1711</spage><epage>1717</epage><pages>1711-1717</pages><issn>0931-041X</issn><eissn>1432-198X</eissn><abstract>The aim of this investigation was to evaluate the impact of recombinant human growth hormone (rhGH) therapy on height velocity (HV), estimated glomerular filtration rate (eGFR) and body mass index (BMI) in a large cohort of children with chronic kidney disease (CKD). We reviewed longitudinal data from patients enrolled in the chronic renal insufficiency registry of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Of the 7189 patients enrolled in the registry, 827 (11.5%) received rhGH. A total of 787 children with CKD previously rhGH naïve who received rhGH for 1–4 years (median 1.5 years) were paired with 787 control patients, and over 100 of the case–controls were followed for 4 years. The control group was matched for age, gender, height and length of time in the NAPRTCS registry. Height velocity was also compared to the general U.S. population. The eGFR of the treated group (37.5 ml/min per 1.73 m
2
) was significantly less than that of the control group (42.3 ml/min per 1.73 m
2
;
p
< 0.001). The rhGH-treated group had a significantly greater HV standard deviation score (SDS) than the control group (
p
< 0.01) at each 6-months post-rhGH treatment initiation point for 2.5 years (
p
< 0.007). Among 220 pairs at 2 years, the height SDS of the rhGH group was 0.56 SDS higher than that of the control group (
p
< 0.05). Treatment with rhGH had no significant impact on the BMI or eGFR. As demonstrated in smaller cohorts, rhGH usage is associated with improved HV in children with CKD. In contrast, rhGH does not appear to have any impact on BMI or kidney function in this population of patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>19387689</pmid><doi>10.1007/s00467-009-1183-0</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-041X |
| ispartof | Pediatric nephrology (Berlin, West), 2009-09, Vol.24 (9), p.1711-1717 |
| issn | 0931-041X 1432-198X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20702933 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Age Body Height - drug effects Body Height - physiology Body Mass Index Care and treatment Child Chronic kidney failure Cohort Studies Collaboration Complications and side effects Creatinine Female Gender Glomerular Filtration Rate - drug effects Growth Disorders - drug therapy Growth Disorders - etiology Growth Disorders - physiopathology Growth hormones Health aspects Human Growth Hormone - therapeutic use Humans Kidney diseases Kidney Failure, Chronic - complications Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - physiopathology Kidney transplants Male Medicine & Public Health Nephrology North America Original Article Pediatrics Recombinant Proteins - therapeutic use Registries Somatotropin Treatment Outcome Urology Velocity |
| title | The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T23%3A46%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20rhGH%20on%20height%20velocity%20and%20BMI%20in%20children%20with%20CKD:%20a%20report%20of%20the%20NAPRTCS%20registry&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=Seikaly,%20Mouin%20G.&rft.date=2009-09-01&rft.volume=24&rft.issue=9&rft.spage=1711&rft.epage=1717&rft.pages=1711-1717&rft.issn=0931-041X&rft.eissn=1432-198X&rft_id=info:doi/10.1007/s00467-009-1183-0&rft_dat=%3Cgale_proqu%3EA382151602%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222278726&rft_id=info:pmid/19387689&rft_galeid=A382151602&rfr_iscdi=true |